Head to Head Contrast: Catalyst Biosciences (NASDAQ:CBIO) versus Boston Therapeutics (NASDAQ:BTHE)

Catalyst Biosciences (NASDAQ:CBIO) and Boston Therapeutics (OTCMKTS:BTHE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Insider & Institutional Ownership

62.7% of Catalyst Biosciences shares are held by institutional investors. 4.6% of Catalyst Biosciences shares are held by insiders. Comparatively, 15.7% of Boston Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Catalyst Biosciences and Boston Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Catalyst Biosciences N/A -42.29% -40.30%
Boston Therapeutics -8,042.35% N/A -104.81%

Earnings and Valuation

This table compares Catalyst Biosciences and Boston Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Catalyst Biosciences $10,000.00 6,680.90 -$30.06 million ($2.68) -2.07
Boston Therapeutics $30,000.00 30.01 -$3.60 million N/A N/A

Boston Therapeutics has higher revenue and earnings than Catalyst Biosciences.

Volatility and Risk

Catalyst Biosciences has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500. Comparatively, Boston Therapeutics has a beta of -0.49, indicating that its share price is 149% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Catalyst Biosciences and Boston Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Catalyst Biosciences 0 0 3 0 3.00
Boston Therapeutics 0 0 0 0 N/A

Catalyst Biosciences currently has a consensus price target of $24.33, suggesting a potential upside of 337.65%. Given Catalyst Biosciences’ higher possible upside, research analysts plainly believe Catalyst Biosciences is more favorable than Boston Therapeutics.

Summary

Catalyst Biosciences beats Boston Therapeutics on 7 of the 11 factors compared between the two stocks.

About Catalyst Biosciences

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors. The company is also developing Dalcinonacog alfa, a Factor IX drug, which has completed enrollment of a Phase I/II subcutaneous dosing trial for the prophylactic treatment of individuals with hemophilia B; CB 2679d-GT, a FIX gene therapy for the treatment of hemophilia B; and CB 2782, an anti-C3 protease program for the treatment of dry age-related macular degeneration (AMD), as well as CB 1965a, a Factor Xa therapeutic program used as a universal procoagulant. Catalyst Biosciences, Inc. has collaboration agreement with Pfizer, Inc. for the development of human Factor VIIa products; and ISU Abxis. The company has strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other retinal diseases. The company was founded in 2002 and is headquartered in South San Francisco, California.

About Boston Therapeutics

Boston Therapeutics, Inc., a pre-clinical and clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements in the United States. Its lead pharmaceutical drug candidates include BTI-320, a non-systemic, carbohydrate-based compound that is in Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic and pre diabetic patients; BTI-410, a peptide injectable compound that has completed Phase Ib clinical trials for type 1 immunosuppression therapy after kidney transplant surgery and type 2 diabetes patients; and IPOXYN, a carbohydrate-based, injectable drug to prevent necrosis, or cell death, as well as to treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications. The company also develops OxyFex, an oxygen delivery agent for ischemia and trauma for blood loss during surgery in veterinary medicine applications. In addition, it produces and sells SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement to support healthy post-meal blood glucose. The company was formerly known as Avanyx Therapeutics, Inc. and changed its name to Boston Therapeutics, Inc. in November 2010. Boston Therapeutics, Inc. was founded in 2009 and is headquartered in Lawrence, Massachusetts.

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.